On July 29, Humana declined 7% in regular trading. The stock came under pressure despite reporting Q2 results that exceeded consensus estimates.
Humana posted Q2 adjusted EPS of $7.61, beating the $7.22 analyst estimate, while revenue of $40.87 billion topped the $40.57 billion consensus. However, the company only reaffirmed its full-year adjusted EPS guidance of at least $9, without raising expectations. With the stock having more than doubled from its 52-week low of $163.11 and multiple institutions recently raising price targets, the market had widely anticipated a guidance increase. The decision to merely reaffirm triggered profit-taking. Additionally, the company disclosed that its Q3 insurance segment benefit ratio is expected to slightly exceed 94%, signaling potential near-term margin pressure from elevated medical costs.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
